This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
I
Downloadable Resources for Follicular Lymphoma (FL)
Tepkinly dosing and administration guide for FL
A digital guide to dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly, along with important safety information.
Tepkinly patient information booklet for FL
A booklet for you to download and pass onto your patients who have been prescribed Tepkinly. It contains information that can be referred to throughout treatment, including understanding the Tepkinly treatment routine and possible side effects. This is for use in conjunction with the patient information leaflet.
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Abbreviations
DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; R/R=relapsed/refractory.
References
- Tepkinly Summary of Product Characteristics.
UK-EPCOR-260122. Date of preparation: March 2026.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
